United Therapeutics Corp (UTHR) Stock Price
UTHRStock
$515.46+67.77%52W
Market Cap$22.11B
P/E16.73x
PEG Ratio2.22
Div yield—
Beta0.50
UTHR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-3.05%
Price vs S&P 500 (4W)-1.71%
PEG Ratio2.22
VGM Score57.52
P/E Ratio (Annual)16.73x
UTHR Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $6.86 | $7.27 | +5.95%(+$0.41) | |
| Q1 2026 | $6.86 | $5.82 | -15.13%(-$1.04) | |
| Q4 2025 | $6.76 | $7.70 | +13.99%(+$0.94) | |
| Q3 2025 | $6.96 | $7.16 | +2.86%(+$0.20) | |
| Q2 2025 | $6.94 | $6.41 | -7.65%(-$0.53) |
UTHR Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.09
4.09
4.09
4.09
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
UTHRUnited Therapeutics Corp | C | C | B | $515.46 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About United Therapeutics Corp
United Therapeutics Corp develops and markets therapies for pulmonary arterial hypertension (PAH), a rare and progressive lung disease characterized by elevated blood pressure in the pulmonary arteries. The company's portfolio centers on treprostinil-based treatments, with Tyvaso DPI (inhalation powder) as its primary revenue driver, supported by Remodulin (injection), Orenitram (extended-release tablets), Adcirca (tadalafil), and Unituxin. The U.S. market generates the majority of revenue, though the company maintains a presence in international markets.